Pitch deck design — Healthcare
A studio service
Healthcare pitch deck design where clinical evidence meets capital.
Healthcare decks are read by clinicians who became investors. They know when the clinical narrative is loose and when the regulatory timeline is wishful. We design healthcare decks that hold up to medical due diligence — not just financial diligence.
N° 01What healthcare decks get wrong
Four design failures that lose life-sciences investors.
01
Regulatory timelines without milestones
A slide that says '510(k) submission Q3 2025' with no milestone preceding it is a red flag, not a plan. Design the regulatory pathway as a Gantt — pre-submission meeting, submission, FDA review, clearance — each dated and owned.
02
Clinical data without study context
p < 0.05 is not a headline. Study type, comparator, n-size, and primary endpoint are the context. Design the data slide to answer 'compared to what, in how many patients, measuring what.'
03
Reimbursement slide missing or last
For device and diagnostic investors, reimbursement is part of the business model. It belongs in the first half of the deck — not as a backup slide. Design it to show CPT codes, CMS rates, and payer strategy in a single legible view.
04
Consumer health aesthetics
Green crosses, stock hospital photography, and empathy-first design signal consumer health, not clinical-stage innovation. Healthcare investors respond to editorial precision, not wellness branding.
N° 02Who this is for
Every modality. Every stage.
01
Medical device founders
Pre-submission through post-clearance commercial raises. Regulatory pathway, clinical evidence, reimbursement, and competitive positioning each need their own dedicated design treatment.
02
Digital health companies
Software-as-a-medical-device (SaMD), AI diagnostics, remote monitoring. Real-world evidence and payer strategy replace the traditional clinical trial narrative.
03
Pharma and drug-discovery ventures
Pre-IND through Phase 2 VC raises. Pipeline clarity, mechanism of action, and probability-of-success framing matter as much as in biotech decks.
Sample slides
Six slide archetypes, in house style.
Generated in our editorial discipline — framed to your vertical. Every deck we ship is original and bespoke.
Investment
Fixed price. No surprises.
Healthcare pitch deck — from $4,800.
- 14–18 finished slides
- Regulatory pathway visualisation
- Clinical evidence design
- Reimbursement landscape slide
- Editable source files
- One revision round
Questions
The answers we give most often.
- How do I present regulatory pathway without sounding uncertain?
- Map the pathway as a Gantt: FDA/CE submission type, expected timeline, submission date, approval date. Specificity signals preparedness, not uncertainty.
- How should I frame clinical evidence at different stages?
- Pre-clinical: show mechanism and animal data with translation caveats. Early clinical: pilot endpoints and n-size. Pivotal: primary and secondary endpoints, p-value, comparator. Each stage has a different investor question.
- Do I need a reimbursement slide?
- For medical devices and diagnostics, yes. Existing CPT coding, CMS average payment, payer landscape, and coverage pathway. For digital health tools, it becomes 'payer strategy.'
- How do I present competitive clinical evidence without a comparative trial?
- A feature matrix comparing your product to the standard of care on clinical dimensions — sensitivity, specificity, time-to-result, cost. Label the data source for each column.
- How long should a healthcare investor deck be?
- 14–18 slides for a Series A medical device or digital health raise. The extra slides vs software come from regulatory pathway, clinical evidence, reimbursement, and IP coverage — each earns its place.
- What's the right design tone for a healthcare deck?
- Clinical and editorial — how a leading medical journal covers innovation. Avoid consumer health aesthetics. Use typography and data visualisation to signal precision.
Next step
Ready to build the healthcare deck?
Send us your clinical data and we'll structure a deck that holds up to life-sciences diligence.